Enstilar Scalp Formulation Clarification
Enstilar for scalp psoriasis is available as a GEL formulation, which is technically classified as a "topical suspension" in FDA terminology—it is NOT the ointment. 11
Understanding the Formulation Terminology
The confusion arises from FDA labeling conventions versus common clinical terminology:
- Enstilar comes in THREE distinct formulations:
- Foam (aerosol) - for body/trunk psoriasis
- Gel/Topical Suspension - specifically designed for scalp psoriasis
- Ointment - older formulation for body psoriasis
The scalp product you're asking about is the GEL, which the FDA labels as a "topical suspension" in official documentation. These terms are used interchangeably for the same scalp formulation. 11
Clinical Guideline Support
The AAD-NPF 2021 guidelines specifically recommend "calcipotriene plus betamethasone dipropionate gel" for 4-12 weeks for scalp psoriasis treatment (Grade A recommendation). 2 This confirms the gel/suspension formulation is the appropriate scalp-specific product.
Key Formulation Differences
Why the gel matters for scalp use:
- Gels are preferred by patients with scalp psoriasis due to cosmetic features—they don't leave the greasy residue that ointments do 3
- The gel formulation allows easier application through hair and better patient adherence
- The foam formulation, while having superior bioavailability for body psoriasis, is primarily indicated for trunk/limbs 45
Common pitfall: Don't confuse the newer foam formulation (Enstilar Foam) with the scalp gel—they are distinct products with different FDA indications, though both contain the same active ingredients (calcipotriene 50 mcg/g + betamethasone dipropionate 0.5 mg/g).